selegiline indications/contra

Stem definitionDrug idCAS RN
monoamine oxydase (MAO)-inhibitors type B 2429 14611-51-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • selegiline
  • (-)-deprenil
  • (-)-deprenyl
  • (-)-selegiline
  • (r)-(-)-deprenyl
  • (r)-selegiline
  • anipryl
  • l-deprenyl
  • selegina
  • selgene
  • zelapar
  • selegiline hydrochloride
  • selegiline HCl
A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl.
  • Molecular weight: 187.29
  • Formula: C13H17N
  • CLOGP: 2.84
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 0
  • TPSA: 3.24
  • ALOGS: -3.87
  • ROTB: 4

Drug dosage:

DoseUnitRoute
5 mg O

Approvals:

DateAgencyCompanyOrphan
June 5, 1989 FDA SOMERSET

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Application site rash 294.31 47.37 45 467 1066 3384281
Application site erythema 238.73 47.37 41 471 2026 3383321
Application site pruritus 128.17 47.37 23 489 1439 3383908
Dyskinesia 106.52 47.37 26 486 7259 3378088
Hallucination, visual 102.50 47.37 23 489 4453 3380894
Application site irritation 98.99 47.37 17 495 819 3384528
Hypersexuality 87.34 47.37 14 498 439 3384908
Gambling disorder 85.17 47.37 14 498 515 3384832
Depression 77.07 47.37 30 482 39740 3345607
Application site reaction 76.03 47.37 13 499 608 3384739
Parkinsonism hyperpyrexia syndrome 75.97 47.37 9 503 23 3385324
Tremor 75.61 47.37 27 485 28117 3357230
Drug interaction 68.94 47.37 29 483 46783 3338564
Dopamine dysregulation syndrome 61.38 47.37 9 503 153 3385194
Hyperhidrosis 60.88 47.37 22 490 23588 3361759
Hallucination 56.28 47.37 18 494 13322 3372025
Orthostatic hypotension 53.72 47.37 14 498 5022 3380325
Application site urticaria 53.41 47.37 8 504 158 3385189
On and off phenomenon 50.80 47.37 8 504 222 3385125
Drug effect decreased 49.85 47.37 16 496 11953 3373394
Parkinson's disease 48.25 47.37 11 501 2260 3383087

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC N04BD01 NERVOUS SYSTEM
ANTI-PARKINSON DRUGS
DOPAMINERGIC AGENTS
Monoamine oxidase B inhibitors
FDA EPC N0000175744 Monoamine Oxidase Inhibitor
FDA EPC N0000175762 Monoamine Oxidase Type B Inhibitor
FDA MoA N0000175761 Monoamine Oxidase-B Inhibitors
MeSH PA D018726 Anti-Dyskinesia Agents
MeSH PA D000978 Antiparkinson Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D008996 Monoamine Oxidase Inhibitors
MeSH PA D018696 Neuroprotective Agents
MeSH PA D020011 Protective Agents

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Parkinson's disease indication 49049000 DOID:14330
Major depressive disorder indication 370143000
Suicidal thoughts contraindication 6471006
Bipolar disorder contraindication 13746004 DOID:3312
Orthostatic hypotension contraindication 28651003
Conduction disorder of the heart contraindication 44808001
Psychotic disorder contraindication 69322001
Kidney disease contraindication 90708001 DOID:2527
Tardive dyskinesia contraindication 102449007
Angina pectoris contraindication 194828000
Mania contraindication 231494001
Disease of liver contraindication 235856003 DOID:409
Pheochromocytoma contraindication 302835009
Malignant melanoma contraindication 372244006 DOID:1909

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.6 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Amine oxidase [flavin-containing] B Enzyme INHIBITOR Ki 7.26 CHEMBL CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 6.76 DRUG MATRIX
Amine oxidase [flavin-containing] A Enzyme Ki 5.04 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 6.17 DRUG MATRIX
Amine oxidase [flavin-containing] A Enzyme Ki 4.98 CHEMBL
Amine oxidase [flavin-containing] A Enzyme Ki 5.42 CHEMBL
Amine oxidase [flavin-containing] B Enzyme Ki 6.01 CHEMBL
Amine oxidase [flavin-containing] B Enzyme Ki 5.87 CHEMBL
Monoamine oxidase Enzyme IC50 7.89 CHEMBL

External reference:

scroll-->
IDSource
CHEBI:50217 CHEBI
4019929 VUID
N0000148014 NUI
C0036579 UMLSCUI
6639 IUPHAR_LIGAND_ID
D00785 KEGG_DRUG
2K1V7GP655 UNII
4436 INN_ID
14611-52-0 SECONDARY_CAS_RN
DB01037 DRUGBANK_ID
CHEMBL972 ChEMBL_ID
26757 PUBCHEM_CID
4019929 VANDF
21238 MMSL
9639 RXNORM
108466000 SNOMEDCT_US
372497003 SNOMEDCT_US
d00976 MMSL
N0000006101 NDFRT
N0000148014 NDFRT
004599 NDDF
CHEMBL1200904 ChEMBL_ID
D012642 MESH_DESCRIPTOR_UI

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
ZELAPAR HUMAN PRESCRIPTION DRUG LABEL 1 0187-0453 TABLET, ORALLY DISINTEGRATING 1.25 mg ORAL NDA 17 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-9290 TABLET 5 mg ORAL ANDA 11 sections
Eldepryl HUMAN PRESCRIPTION DRUG LABEL 1 49502-420 CAPSULE 5 mg ORAL NDA 11 sections
EMSAM HUMAN PRESCRIPTION DRUG LABEL 1 49502-900 PATCH 6 mg TRANSDERMAL NDA 22 sections
EMSAM HUMAN PRESCRIPTION DRUG LABEL 1 49502-901 PATCH 9 mg TRANSDERMAL NDA 22 sections
EMSAM HUMAN PRESCRIPTION DRUG LABEL 1 49502-902 PATCH 12 mg TRANSDERMAL NDA 22 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-2918 TABLET 5 mg ORAL ANDA 11 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51862-146 TABLET 5 mg ORAL ANDA 13 sections
SELEGILINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 55700-076 CAPSULE 5 mg ORAL ANDA 10 sections
SELEGILINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 60429-019 CAPSULE 5 mg ORAL ANDA 11 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 60429-176 TABLET 5 mg ORAL ANDA 11 sections
SELEGILINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 60505-0055 CAPSULE 5 mg ORAL ANDA 11 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 60505-3438 TABLET 5 mg ORAL ANDA 11 sections
SELEGILINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 67253-700 CAPSULE 5 mg ORAL ANDA 11 sections
SELEGILINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 68151-2649 CAPSULE 5 mg ORAL ANDA 11 sections